In his last year as President, Obama has tasked Vice President Joe Biden with one of the most important scientific initiatives of our time. In four years’ time and just over fifty years after the original Moonshot, Biden hopes to reach a hypothetical moon by finding a cure for cancer.
Since then, VP Biden has been hard at work collaborating with our nation’s top doctors, researchers, and health organizations in order to set the Moonshot up for success. The goals set forward by the Vice President for the initiative are
Accelerate our understanding of cancer and its prevention, early detection, treatment, and cure
Improve patient access and care
Support greater access to new research, data, and computational capabilities
Encourage development of cancer treatments
Identify and address any unnecessary regulatory barriers and consider ways to expedite administrative reforms
Ensure optimal investment of federal resources
Identify opportunities to develop public-private partnerships and increase coordination of the federal government's efforts with the private sector, as appropriate.
The U.S. government’s cancer research network is in severe disarray according to a report by the Institute of Medicine. Waste and inefficiency cause 40% of all late-stage government funded cancer trials to be abandoned before completion, the report found. Shannon Pettypiece at Bloomberg.com and Liz Jones at FierceBiotech say the report paints a doomladen picture.
Scientists have identified seven new genetic variants that appear to be linked with increase risk of prostate cancer. Among these are four new "single-letter" genetic variants on one particular chromosome, called 8q24.
This chromosomal region has previously been associated with breast, colon, and bladder cancer. The discoveries identifying the four new genetic locations associated with prostate cancer on chromosome 8q24 were made by teams of independent scientists around the world. Three separate research papers on the discoveries are published in the online issue of Nature Genetics.
In one of the papers, Rosalind Eeles, from the London, UK Institute of Cancer Research laboratory (ICR) and colleagues in the Genetic Epidemiology Unit, University of Cambridge, report on the discovery of seven new prostate cancer susceptibility loci. In this video Dr. Eeles explains what her team found. She says they plan to take the results "into the clinic" to try to predict which men may need early testing for prostate cancer. Dr. Eeles says 8q is a "very interesting part of the genome for solid cancer risk." ...continue reading "New Genetic Variants Linked with Risk of Prostate Cancer"
the 4th C2 Academic Retreat (C2R) being organized jointly by the Canadian Urologic Oncology Group (CUOG) and the Canadian Urology Research Consortium (CURC) is scheduled for the weekend of September 25 to 27, 2009 at the fashionable hotel called W in Montreal.
According to UroToday, "this three-day educational event will include provocative 'Town Hall' sessions on the topics of Hormone Replacement and Cancer Risk, Prostrate Screening Controversies and the use of Robotic Technology in Surgery (Is it ready for prime time?)." "The line-up of topics and the caliber of presenters is unsurpassed in all the years we have been conducting these events," says Dr. Laurence Klotz, Chair of the CURC and immediate past president of the Canadian Urology Association (CUA).
A study published in Clinical Cancer Research August 18 2009 reports that an extract of the Chinese herb Wedelia (a member of the Asteraceae, or sunflower family of plants) shrinks the androgen receptor and prostate cancer in male mice.
Scientists have made a discovery about antibiotics that may advance cancer therapy. By studying the mechanisms at work in protein production, a Princeton-led team has discovered why certain kinds of antibiotics are so effective.
The new discovery exposes how a specific protein protects against cell death. This may also shed light on the cancer-fighting process, because cancer involves inability of defective cells to die off.